Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition - PubMed (original) (raw)
. 2004 Dec;11(12):1192-7.
doi: 10.1038/nsmb859. Epub 2004 Nov 14.
Huifen Chen, Alexander Pavlovsky, Christopher Whitehead, Erli Zhang, Peter Kuffa, Chunhong Yan, Patrick McConnell, Cindy Spessard, Craig Banotai, W Thomas Mueller, Amy Delaney, Charles Omer, Judith Sebolt-Leopold, David T Dudley, Iris K Leung, Cathlin Flamme, Joseph Warmus, Michael Kaufman, Stephen Barrett, Haile Tecle, Charles A Hasemann
Affiliations
- PMID: 15543157
- DOI: 10.1038/nsmb859
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
Jeffrey F Ohren et al. Nat Struct Mol Biol. 2004 Dec.
Erratum in
- Nat Struct Mol Biol. 2005 Mar;12(3):278
Abstract
MEK1 and MEK2 are closely related, dual-specificity tyrosine/threonine protein kinases found in the Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway. Approximately 30% of all human cancers have a constitutively activated MAPK pathway, and constitutive activation of MEK1 results in cellular transformation. Here we present the X-ray structures of human MEK1 and MEK2, each determined as a ternary complex with MgATP and an inhibitor to a resolution of 2.4 A and 3.2 A, respectively. The structures reveal that MEK1 and MEK2 each have a unique inhibitor-binding pocket adjacent to the MgATP-binding site. The presence of the potent inhibitor induces several conformational changes in the unphosphorylated MEK1 and MEK2 enzymes that lock them into a closed but catalytically inactive species. Thus, the structures reported here reveal a novel, noncompetitive mechanism for protein kinase inhibition.
Similar articles
- A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).
Liang H, Liu T, Chen F, Liu Z, Liu S. Liang H, et al. Sci China Life Sci. 2011 Apr;54(4):336-41. doi: 10.1007/s11427-011-4156-z. Epub 2011 Apr 21. Sci China Life Sci. 2011. PMID: 21509657 - MEK1/2 dual-specificity protein kinases: structure and regulation.
Roskoski R Jr. Roskoski R Jr. Biochem Biophys Res Commun. 2012 Jan 6;417(1):5-10. doi: 10.1016/j.bbrc.2011.11.145. Epub 2011 Dec 8. Biochem Biophys Res Commun. 2012. PMID: 22177953 Review. - Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.
Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, Carr D, Zhu H, Wong J, Yang RS, Le HV, Madison VS. Fischmann TO, et al. Biochemistry. 2009 Mar 31;48(12):2661-74. doi: 10.1021/bi801898e. Biochemistry. 2009. PMID: 19161339 - Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Marzec M, et al. Oncogene. 2007 Feb 8;26(6):813-21. doi: 10.1038/sj.onc.1209843. Epub 2006 Aug 7. Oncogene. 2007. PMID: 16909118 - MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Wu PK, Park JI. Wu PK, et al. Semin Oncol. 2015 Dec;42(6):849-62. doi: 10.1053/j.seminoncol.2015.09.023. Epub 2015 Sep 24. Semin Oncol. 2015. PMID: 26615130 Free PMC article. Review.
Cited by
- Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib.
Gazzin A, Fornari F, Cardaropoli S, Carli D, Tartaglia M, Ferrero GB, Mussa A. Gazzin A, et al. Life (Basel). 2024 Jun 6;14(6):731. doi: 10.3390/life14060731. Life (Basel). 2024. PMID: 38929714 Free PMC article. Review. - Mechanistic and structural understanding of uncompetitive inhibitors of caspase-6.
Heise CE, Murray J, Augustyn KE, Bravo B, Chugha P, Cohen F, Giannetti AM, Gibbons P, Hannoush RN, Hearn BR, Jaishankar P, Ly CQ, Shah K, Stanger K, Steffek M, Tang Y, Zhao X, Lewcock JW, Renslo AR, Flygare J, Arkin MR. Heise CE, et al. PLoS One. 2012;7(12):e50864. doi: 10.1371/journal.pone.0050864. Epub 2012 Dec 5. PLoS One. 2012. PMID: 23227217 Free PMC article. - A novel approach to the discovery of small-molecule ligands of CDK2.
Martin MP, Alam R, Betzi S, Ingles DJ, Zhu JY, Schönbrunn E. Martin MP, et al. Chembiochem. 2012 Sep 24;13(14):2128-36. doi: 10.1002/cbic.201200316. Epub 2012 Aug 14. Chembiochem. 2012. PMID: 22893598 Free PMC article. - Emerging Computational Methods for the Rational Discovery of Allosteric Drugs.
Wagner JR, Lee CT, Durrant JD, Malmstrom RD, Feher VA, Amaro RE. Wagner JR, et al. Chem Rev. 2016 Jun 8;116(11):6370-90. doi: 10.1021/acs.chemrev.5b00631. Epub 2016 Apr 13. Chem Rev. 2016. PMID: 27074285 Free PMC article. Review. - The MEK2-binding tumor suppressor hDlg is recruited by E-cadherin to the midbody ring.
Gaudet S, Langlois MJ, Lue RA, Rivard N, Viel A. Gaudet S, et al. BMC Cell Biol. 2011 Dec 20;12:55. doi: 10.1186/1471-2121-12-55. BMC Cell Biol. 2011. PMID: 22185284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous